Analyst consensus rating

Filana Therapeutics Analyst Rating: Strong Buy

Direct answer

Filana Therapeutics's consensus rating is Strong Buy.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.50.
Forecast evidence checked November 18, 2026.

Get free Filana Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$0.48
Average price target
$6.50
High price target
$8.00
Low price target
$5.00
Low target gap
+939.7%
Target upside
+1,251.6%
High target gap
+1,563.5%
Target range width
623.8%
Consensus rating
Strong Buy
Analysts
2
Evidence date
November 18, 2026
Valid through
November 25, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Filana Therapeutics?

Filana Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.50.

How far are Filana Therapeutics's low and high targets from the recorded price?

The low target implies +939.7%, while the high target implies +1,563.5%.

How many analysts are included in Filana Therapeutics's consensus?

The verified consensus includes 2 analysts.

How is Filana Therapeutics's target upside or downside calculated?

The average target of $6.50 is divided by the recorded price of $0.48, then one is subtracted to produce +1,251.6%. This does not guarantee a future return.

When was Filana Therapeutics's analyst forecast verified?

The data was verified on 2026-11-18. The dataset is valid through 2026-11-25.